Recent advances in the use of opioids for cancer pain

References

• World Health OrganizationCancer Pain Relief2nd edWorld Health Organization1996
   Google Scholar
• ZechDFGrondSLynchJHertelDLehmannKAValidation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective studyPain199563165768577492
   PubMed Web of Science ®Google Scholar
• MeuserTPietruckCRadbruchLStutePLehmannKAGrondSSymptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiologyPain200193324725711514084
   PubMed Web of Science ®Google Scholar
• HanksGWConnoFChernyNHannaMKalsoEMcQuayHJMorphine and alternative opioids in cancer pain: the EAPC recommendationsBr J Cancer200184558759311237376
   PubMed Web of Science ®Google Scholar
• JoransonDEAvailability of opioids for cancer pain: recent trends, assessment of system barriers, New World Health Organization guidelines, and the risk of diversionJ Pain Symptom Manage1993863533607525750
   PubMed Web of Science ®Google Scholar
• International Narcotics Control Board ARPr, United NationsNarcotic drugs – estinated world requirements for 2008 – statistics for 2006Part 4: Statistical information on narcotic drugsInternational Narcotics Control Board2007 [cited 2009 Jun 9]; Available from: URL: www.incb.org/pdf/technical-reports/narcotic-drugs/2007/part_four_2007.pdf
   Google Scholar
• Von RoennJHCleelandCSGoninRHatfieldAKPandyaKJPhysician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology GroupAnn Intern Med199311921211268099769
   PubMed Web of Science ®Google Scholar
• International Narcotics Control Board ARPrEnsuring access to pain treatment is vital and possible says INCBInternational Narcotics Control Board2008 [cited 2009 Jun 9]; Available from: URL: www.incb.org/pdf/annual-report/2007/en/04-press-release.pdf
   Google Scholar
• StjernswardJWHO cancer pain relief programmeCancer Surv1988711952082454740
   PubMedGoogle Scholar
• World Health OrganizationCancer Pain Relief With a Guide to Opioid Availability2nd edGeneva1996
   Google Scholar
• KlepstadPKaasaSChernyNHanksGDeCFPain and pain treatments in European palliative care units. A cross sectional survey from the European Association for Palliative Care Research NetworkPalliat Med200519647748416218160
   PubMed Web of Science ®Google Scholar
• HamunenKLaitinen-ParkkonenPPaakkariPBreivikHGordhTJensenNHWhat do different databases tell about the use of opioids in seven European countries in 2002?Eur J Pain200812670571518162422
   PubMed Web of Science ®Google Scholar
• ChernyNRipamontiCPereiraJDavisCFallonMMcQuayHStrategies to manage the adverse effects of oral morphine: an evidence-based reportJ Clin Oncol20011992542255411331334
   PubMed Web of Science ®Google Scholar
• MercadanteSBrueraEOpioid switching: a systematic and critical reviewCancer Treat Rev200632430431516624490
   PubMed Web of Science ®Google Scholar
• KlokeMRappMBosseBKlokeOToxicity and/or insufficient analgesia by opioid therapy: risk factors and the impact of changing the opioid. A retrospective analysis of 273 patients observed at a single centerSupport Care Cancer20008647948611094993
   PubMed Web of Science ®Google Scholar
• MercadanteSFerreraPVillariPCasuccioAIntravaiaGMangioneSFrequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unitJ Pain Symptom Manage200937463264119345298
   PubMed Web of Science ®Google Scholar
• QuigleyCOpioid switching to improve pain relief and drug tolerabilityCochrane Database Syst Rev20043CD00484715266542
   PubMedGoogle Scholar
• RileyJRossJRRutterDWellsAUGollerKDuBRNo pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patientsSupport Care Cancer2006141566415952009
   PubMed Web of Science ®Google Scholar
• de StoutzNDBrueraESuarez-AlmazorMOpioid rotation for toxicity reduction in terminal cancer patientsJ Pain Symptom Manage19951053783847673770
   PubMed Web of Science ®Google Scholar
• Benitez-RosarioMASalinas-MartinAguirre-JaimeAPerez-MendezLFeriaMMorphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factorsJ Pain Symptom Manage20093761061106819171458
   PubMed Web of Science ®Google Scholar
• WirzSWartenbergHCElsenCWittmannMDiederichsMNadstawekJManaging cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trialClin J Pain200622977077517057558
   PubMed Web of Science ®Google Scholar
• AndersonRSaiersJHAbramSSchlichtCAccuracy in equianalgesic dosing. conversion dilemmasJ Pain Symptom Manage200121539740611369161
   PubMed Web of Science ®Google Scholar
• GammaitoniARFinePAlvarezNMcPhersonMLBergmarkSClinical application of opioid equianalgesic dataClin J Pain200319528629712966254
   PubMed Web of Science ®Google Scholar
• RossJRRileyJQuigleyCWelshKIClinical pharmacology and pharmacotherapy of opioid switching in cancer patientsOncologist200611776577316880235
   PubMed Web of Science ®Google Scholar
• MercadanteSOpioid rotation for cancer pain: rationale and clinical aspectsCancer19998691856186610547561
   PubMed Web of Science ®Google Scholar
• NarabayashiMSaijoYTakenoshitaSChidaMShimoyamaNMiuraTOpioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trialJpn J Clin Oncol200838429630418326541
   PubMed Web of Science ®Google Scholar
• KasaiSHayashidaMSoraIIkedaKCandidate gene polymorphisms predicting individual sensitivity to opioidsNaunyn Schmiedebergs Arch Pharmacol20083774–626928117999051
   PubMed Web of Science ®Google Scholar
• InnocentiFUndeviaSDIyerLChenPXDasSKocherginskyMGenetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecanJ Clin Oncol20042281382138815007088
   PubMed Web of Science ®Google Scholar
• IyerLDasSJanischLWenMRamirezJKarrisonTUGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicityPharmacogenomics J200221434711990381
   PubMedGoogle Scholar
• SchwarzUIRitchieMDBradfordYLiCDudekSMFrye-AndersonAGenetic determinants of response to warfarin during initial anticoagulationN Engl J Med200835810999100818322281
   PubMed Web of Science ®Google Scholar
• DayerPDesmeulesJLeemannTStriberniRBioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)Biochem Biophys Res Commun198815214114163358767
   PubMed Web of Science ®Google Scholar
• SindrupSHBrosenKBjerringPrendt-NielsenLLarsenUAngeloHRCodeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteineClin Pharmacol Ther19904866866932249379
   PubMed Web of Science ®Google Scholar
• KirchheinerJSchmidtHTzvetkovMKeulenJTLotschJRootsIPharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplicationPharmacogenomics J20077425726516819548
   PubMed Web of Science ®Google Scholar
• KorenGCairnsJChitayatDGaedigkALeederSJPharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed motherLancet2006368953670416920476
   PubMed Web of Science ®Google Scholar
• MadadiPRossCJHaydenMRCarletonBCGaedigkALeederJSPharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control studyClin Pharmacol Ther2009851313518719619
   PubMed Web of Science ®Google Scholar
• SachseCBrockmollerJBauerSRootsICytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequencesAm J Hum Genet19976022842959012401
   PubMed Web of Science ®Google Scholar
• StamerUMLehnenKHothkerFBayererBWolfSHoeftAImpact of CYP2D6 genotype on postoperative tramadol analgesiaPain20031051–223123814499440
   PubMed Web of Science ®Google Scholar
• StamerUMStuberFMudersTMusshoffFRespiratory depression with tramadol in a patient with renal impairment and CYP2D6 gene duplicationAnesth Analg2008107392692918713907
   PubMed Web of Science ®Google Scholar
• SkorpenFLaugsandEAKlepstadPKaasaSVariable response to opioid treatment: any genetic predictors within sight?Palliat Med200822431032718541635
   PubMed Web of Science ®Google Scholar
• RivaAKohaneISA SNP-centric database for the investigation of the human genomeBMC Bioinformatics200426;533
   Web of Science ®Google Scholar
• ChaturvediKShahrestanifarMHowellsRDμ opioid receptor: role for the amino terminus as a determinant of ligand binding affinityMol Brain Res200076647210719216
   PubMedGoogle Scholar
• MayerPHolltVPharmacogenetics of opioid receptors and addictionPharmacogenet Genomics20061611716344716
   PubMed Web of Science ®Google Scholar
• NCBIHapMap frequency data on SNP databbase, NCBI (National Centre for Biotechnology Information)NCBI2009 [cited 2009 Jun 20]; Available from: URL: www.ncbi.nlm.nih.gov
   Google Scholar
• ZhangYWangDJohnsonADPappACSadeeWAllelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118GJ Biol Chem200528038326183262416046395
   PubMed Web of Science ®Google Scholar
• BondCLaForgeKSTianMMeliaDZhangSBorgLSingle-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addictionProc Natl Acad Sci U S A19989516960896139689128
   PubMed Web of Science ®Google Scholar
• BefortKFilliolDDecaillotFMGaveriaux-RuffCHoeheMRKiefferBLA single nucleotide polymorphic mutation in the human [micro]-opioid receptor severely impairs receptor signalingJ Biol Chem200127653130313711067846
   PubMed Web of Science ®Google Scholar
• KlepstadPRakvagTTKaasaSHoltheMDaleOBorchgrevinkPCThe 118 A > G polymorphism in the human micro-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant diseaseActa Anaesthesiol Scand200448101232123915504181
   PubMed Web of Science ®Google Scholar
• CampaDGioiaATomeiAPoliPBaraleRAssociation of ABCB1/ MDR1 and OPRM1 gene polymorphisms with morphine pain reliefClin Pharmacol Ther200883455956617898703
   PubMed Web of Science ®Google Scholar
• Reyes-GibbyCCSheteSRakvagTBhatSVSkorpenFBrueraEExploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT genePain20071301–2253017156920
   PubMed Web of Science ®Google Scholar
• LotschJSkarkeCGroschSDarimontJSchmidtHGeisslingerGThe polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphinePharmacogenetics20021213911773859
   PubMedGoogle Scholar
• PasternakGWIncomplete cross tolerance and multiple mu opioid peptide receptorsTrends Pharmacol Sci2001222677011166849
   PubMed Web of Science ®Google Scholar
• PortoghesePSLarsonDLSayreLMFriesDSTakemoriAEA novel opioid receptor site directed alkylating agent with irreversible narcotic antagonistic and reversible agonistic activitiesJ Med Chem19802332332346245210
   PubMed Web of Science ®Google Scholar
• ClarkeSKitchenIOpioid analgesia: new information from gene knockout studiesCurr Opin Anaesthesiol19991260961417016257
   PubMedGoogle Scholar
• IkedaKIdeSHanWHayashidaMUhlGRSoraIHow individual sensitivity to opiates can be predicted by gene analysesTrends Pharmacol Sci200526631131715925706
   PubMed Web of Science ®Google Scholar
• RossiGCBrownGPLeventhalLYangKPasternakGWNovel receptor mechanisms for heroin and morphine-6 beta-glucuronide analgesiaNeurosci Lett199620;216114
   Web of Science ®Google Scholar
• WangJBJohnsonPSPersicoAMHawkinsALGriffinCAUhlGRHuman mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignmentFEBS Lett199433822172227905839
   PubMed Web of Science ®Google Scholar
• ShabalinaSAZaykinDVGrisPOgurtsovAYGauthierJShibataKExpansion of the human {micro}-opioid receptor gene architecture: novel functional variantsHum Mol Genet20091861037105119103668
   PubMed Web of Science ®Google Scholar
• PasternakGWMolecular biology of opioid analgesiaJ Pain Symptom Manage2005295 SupplS2S915907642
   PubMed Web of Science ®Google Scholar
• RossiGCLeventhalLPanYXColeJSuWBodnarRJAntisense mapping of MOR-1 in rats: distinguishing between morphine and morphine-6beta-glucuronide antinociceptionJ Pharmacol Exp Ther199728111091149103486
   PubMed Web of Science ®Google Scholar
• SchullerAGKingMAZhangJBolanEPanYXMorganDJRetention of heroin and morphine-6 beta-glucuronide analgesia in a new line of mice lacking exon 1 of MOR-1Nature Neuroscience199922151156
   PubMed Web of Science ®Google Scholar
• PasternakGWInsights into mu opioid pharmacology the role of mu opioid receptor subtypesLife Sci20016819–202213221911368076
   PubMed Web of Science ®Google Scholar
• ZhangYPanYXKolesnikovYPasternakGWImmunohistochemical labeling of the mu opioid receptor carboxy terminal splice variant mMOR-1B4 in the mouse central nervous systemBrain Res200610991334316793025
   PubMed Web of Science ®Google Scholar
• PanYXDiversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promotersDNA Cell Biol2005241173675016274294
   PubMed Web of Science ®Google Scholar
• PanLXuJYuRXuMMPanYXPasternakGWIdentification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, OprmNeuroscience2005133120922015893644
   PubMed Web of Science ®Google Scholar
• FricchioneGZhuWCadetPMantioneKJBromfieldEMadsenJIdentification of endogenous morphine and a mu3-like opiate alkaloid receptor in human brain tissue taken from a patient with intractable complex partial epilepsyMed Sci Monit2008146CS454918509280
   PubMed Web of Science ®Google Scholar
• Gaveriaux-RuffCPelusoJBefortKSimoninFZillioxCKiefferBLDetection of opioid receptor mRNA by RT-PCR reveals alternative splicing for the delta- and kappa-opioid receptorsBrain Res Mol Brain Res19974822983049332727
   PubMedGoogle Scholar
• MatthesHWMaldonadoRSimoninFValverdeOSloweSKitchenILoss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor geneNature199638366038198238893006
   PubMed Web of Science ®Google Scholar
• RaynorKKongHChenYYasudaKYuLBellGIPharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptorsMol Pharmacol19944523303348114680
   PubMed Web of Science ®Google Scholar
• SatohMMinamiMMolecular pharmacology of the opioid receptorsPharmacol Ther19956833433648788562
   PubMed Web of Science ®Google Scholar
• KhotibJNaritaMSuzukiMYajimaYSuzukiTFunctional interaction among opioid receptor types: up-regulation of mu-and delta-opioid receptor functions after repeated stimulation of kappa-opioid receptorsNeuropharmacology200446453154014975677
   PubMed Web of Science ®Google Scholar
• RozenfeldRbul-HusnNSGomezIDeviLAAn emerging role for the delta opioid receptor in the regulation of mu opioid receptor functionScientific WorldJournal20077647317982578
   PubMedGoogle Scholar
• ParkPSPalczewskiKDiversifying the repertoire of G protein-coupled receptors through oligomerizationProc Natl Acad Sci U S A2005102258793879415956197
   PubMed Web of Science ®Google Scholar
• GomesIJordanBAGuptaATrapaidzeNNagyVDeviLAHeterodimerization of mu and delta opioid receptors: A role in opiate synergyJ Neurosci20002022RC11011069979
   PubMed Web of Science ®Google Scholar
• ZhuYKingMASchullerAGNitscheJFReidlMEldeRPRetention of supraspinal delta-like analgesia and loss of morphine tolerance in delta opioid receptor knockout miceNeuron199924124325210677041
   PubMed Web of Science ®Google Scholar
• JordanBADeviLAG-protein-coupled receptor heterodimerization modulates receptor functionNature1999399673769770010385123
   PubMed Web of Science ®Google Scholar
• GeorgeSRFanTXieZTseRTamVVargheseGOligomerization of mu- and delta-opioid receptors. Generation of novel functional propertiesJ Biol Chem200027534261282613510842167
   PubMed Web of Science ®Google Scholar
• WaldhoerMFongJJonesRMLunzerMMSharmaSKKostenisEA heterodimer-selective agonist shows in vivo relevance of G protein-coupled receptor dimersProc Natl Acad Sci U S A2005102259050905515932946
   PubMed Web of Science ®Google Scholar
• DaviesANDickmanAReidCStevensAMZeppetellaGThe management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and IrelandEur J Pain200913433133818707904
   PubMed Web of Science ®Google Scholar
• PortenoyRKPayneDJacobsenPBreakthrough pain: characteristics and impact in patients with cancer painPain1999811–212913410353500
   PubMed Web of Science ®Google Scholar
• CaraceniAMartiniCZeccaEPortenoyRKAshbyMAHawsonGBreakthrough pain characteristics and syndromes in patients with cancer pain. An international surveyPalliat Med200418317718315198130
   PubMed Web of Science ®Google Scholar
• ZeppetellaGO’DohertyCACollinsSPrevalence and characteristics of breakthrough pain in cancer patients admitted to a hospiceJ Pain Symptom Manage2000202879210989246
   PubMed Web of Science ®Google Scholar
• ZeppetellaGImpact and management of breakthrough pain in cancerCurr Opin Support Palliat Care2009311619365156
   PubMedGoogle Scholar
• TwycrossRGWilcockACharlesworthSDickmanAPalliative Care Formulary2nd edLondonRadcliffe Medical Press2002
   Google Scholar
• MercadanteSRadbruchLCaraceniAChernyNKaasaSNauckFEpisodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative CareCancer200294383283911857319
   PubMed Web of Science ®Google Scholar
• HaoJHengPWBuccal delivery systemsDrug Dev Ind Pharm200329882183214570303
   PubMed Web of Science ®Google Scholar
• ZhangHZhangJStreisandJBOral mucosal drug delivery: clinical pharmacokinetics and therapeutic applicationsClin Pharmacokinet200241966168012126458
   PubMed Web of Science ®Google Scholar
• StevensRAGhaziSMRoutes of opioid analgesic therapy in the management of cancer painCancer Control20007213214110783817
   PubMedGoogle Scholar
• Electronic Medicines Compendium, CephalonActiq: Summary of product characteristicsElectronic Medicines Compendium2008211 [cited 2009 Jun 13]; Available from: URL: http://emc.medicines.org.uk/medicine/11145/SPC/Actiq/
   Google Scholar
• MystakidouKKatsoudaEParpaEVlahosLTsiatasMLOral transmucosal fentanyl citrate: overview of pharmacological and clinical characteristicsDrug Deliv20061342697616766468
   PubMed Web of Science ®Google Scholar
• StreisandJBVarvelJRStanskiDRLeMLAshburnMAHagueBIAbsorption and bioavailability of oral transmucosal fentanyl citrateAnesthesiology19917522232291859010
   PubMed Web of Science ®Google Scholar
• StreisandJBBuschMAEganTDSmithBGGayMPaceNLDose proportionality and pharmacokinetics of oral transmucosal fentanyl citrateAnesthesiology19988823053099477048
   PubMed Web of Science ®Google Scholar
• FarrarJTClearyJRauckRBuschMNordbrockEOral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patientsJ Natl Cancer Inst19989086116169554444
   PubMed Web of Science ®Google Scholar
• PortenoyRKPayneRColuzziPRaschkoJWLyssABuschMAOral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration studyPain1999792–330331210068176
   PubMed Web of Science ®Google Scholar
• ColuzziPHSchwartzbergLConroyJDCharapataSGayMBuschMABreakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR)Pain2001911–212313011240084
   PubMed Web of Science ®Google Scholar
• ChristieJMSimmondsMPattRColuzziPBuschMANordbrockEDose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent painJ Clin Oncol19981610323832459779697
   PubMed Web of Science ®Google Scholar
• HanksGWNugentMHiggsCMBuschMAOral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use studyPalliat Med200418869870415623166
   PubMed Web of Science ®Google Scholar
• DaviesANVriensJOral transmucosal fentanyl citrate and xerostomiaJ Pain Symptom Manage200530649649716376735
   PubMed Web of Science ®Google Scholar
• DarwishMKirbyMRobertsonPJrTracewellWJiangJGAbsolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrateJ Clin Pharmacol200747334335017322146
   PubMed Web of Science ®Google Scholar
• SlatkinNEXieFMessinaJSegalTJFentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic painJ Support Oncol20075732733417708123
   PubMedGoogle Scholar
• DarwishMKirbyMRobertsonPTracewellWJiangJGAbsorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot studyClin Drug Investig2007279605611
   Web of Science ®Google Scholar
• LennernasBHednerTHolmbergMBredenbergSNystromCLennernasHPharmacokinetics and tolerability of different doses of fentanyl following sublingual administration of a rapidly dissolving tablet to cancer patients: a new approach to treatment of incident painBr J Clin Pharmacol200559224925315676050
   PubMed Web of Science ®Google Scholar
• ZeppetellaGNebulized and intranasal fentanyl in the management of cancer-related breakthrough painPalliat Med2000141575810717724
   PubMed Web of Science ®Google Scholar
• ZeppetellaGAn assessment of the safety, efficacy, and acceptability of intranasal fentanyl citrate in the management of cancer-related breakthrough pain: a pilot studyJ Pain Symptom Manage200020425325811027906
   PubMed Web of Science ®Google Scholar
• GoodPJacksonKBrumleyDAshbyMIntranasal sufentanil for cancer-associated breakthrough painPalliat Med2009231545819144765
   PubMed Web of Science ®Google Scholar
• Gardner-NixJOral transmucosal fentanyl and sufentanil for incident painJ Pain Symptom Manage200122262763011503630
   PubMed Web of Science ®Google Scholar
• KurzASesslerDIOpioid-induced bowel dysfunction: pathophysiology and potential new therapiesDrugs200363764967112656645
   PubMed Web of Science ®Google Scholar
• McMillanSCWilliamsFAValidity and reliability of the Constipation Assessment ScaleCancer Nurs19891231831882743302
   PubMed Web of Science ®Google Scholar
• SykesNPThe pathogenesis of constipationJ Support Oncol20064521321816724641
   PubMedGoogle Scholar
• DroneyJRossJGrettonSWelshKSatoHRileyJConstipation in cancer patients on morphineSupport Care Cancer200816545345918197439
   PubMed Web of Science ®Google Scholar
• ChernyNRipamontiCPereiraJDavisCFallonMMcQuayHStrategies to manage the adverse effects of oral morphine: an evidence-based reportJ Clin Oncol20011992542255411331334
   PubMed Web of Science ®Google Scholar
• ManaraLBianchettiAThe central and peripheral influences of opioids on gastrointestinal propulsionAnnu Rev Pharmacol Toxicol1985252492733890704
   PubMed Web of Science ®Google Scholar
• WatermanSACostaMToniniMModulation of peristalsis in the guinea-pig isolated small intestine by exogenous and endogenous opioidsBr J Pharmacol19921064100410101356564
   PubMed Web of Science ®Google Scholar
• StewartJJWeisbrodtNWBurksTFCentral and peripheral actions of morphine on intestinal transitJ Pharmacol Exp Ther19782053547555660528
   PubMed Web of Science ®Google Scholar
• BasiliscoGBozzaniACamboniGRecchiaMQuatriniMConteDEffect of loperamide and naloxone on mouth-to-caecum transit time evaluated by lactulose hydrogen breath testGut19852677007034018633
   PubMed Web of Science ®Google Scholar
• SterniniCPatiernoSSelmerISKirchgessnerAThe opioid system in the gastrointestinal tractNeurogastroenterol Motil200416 Suppl 231615357847
   PubMed Web of Science ®Google Scholar
• BianchiGFerrettiPRecchiaMRocchettiMTavaniAManaraLMorphine tissue levels and reduction of gastrointestinal transit in rats. Correlation supports primary action site in the gutGastroenterology19838548528586193028
   PubMed Web of Science ®Google Scholar
• RoySLiuHCLohHHmu-Opioid receptor-knockout mice: the role of mu-opioid receptor in gastrointestinal transitBrain Res Mol Brain Res1998561–22812839602153
   PubMedGoogle Scholar
• TatsumiHCostaMSchimerlikMNorthRAPotassium conductance increased by noradrenaline, opioids, somatostatin, and G-proteins: whole-cell recording from guinea pig submucous neuronsJ Neurosci1990105167516821970605
   PubMed Web of Science ®Google Scholar
• SurprenantAShenKZNorthRATatsumiHInhibition of calcium currents by noradrenaline, somatostatin and opioids in guinea-pig submucosal neuronesJ Physiol19904315856081983121
   PubMed Web of Science ®Google Scholar
• HicksGAHaven-HudkinsDLCamilleriMOpiates in the control of gastrointestinal tract function: current knowledge and new avenues for researchNeurogastroenterol Motil200416 Suppl 2677015357854
   PubMed Web of Science ®Google Scholar
• DeLACouparIMInsights into opioid action in the intestinal tractPharmacol Ther19966921031158984506
   PubMed Web of Science ®Google Scholar
• MilesCFellowesDGoodmanMWilkinsonSLaxatives for the management of constipation in palliative care patientsCochrane Database Syst Rev20064CD00344817054172
   PubMed Web of Science ®Google Scholar
• FishmanJRoffwargHHellmanLDisposition of naloxone-7,8,3H in normal and narcotic-dependent menJ Pharmacol Exp Ther197318735755804588968
   PubMed Web of Science ®Google Scholar
• MossJRosowCEDevelopment of peripheral opioid antagonists’ new insights into opioid effectsMayo Clin Proc200883101116113018828971
   PubMed Web of Science ®Google Scholar
• Culpepper-MorganJAInturrisiCEPortenoyRKFoleyKHoudeRWMarshFTreatment of opioid-induced constipation with oral naloxone: a pilot studyClin Pharmacol Ther199252190951623695
   PubMed Web of Science ®Google Scholar
• LataschLZimmermannMEberhardtBJurnaITreament of morphine-induced constipation with oral naloxoneAnaesthesist19974631911949163262
   PubMed Web of Science ®Google Scholar
• SykesNPAn investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancerPalliat Med19961021351448800821
   PubMed Web of Science ®Google Scholar
• MeissnerWSchmidtUHartmannMKathRReinhartKOral naloxone reverses opioid-associated constipationPain200084110510910601678
   PubMed Web of Science ®Google Scholar
• LiuMWittbrodtELow-dose oral naloxone reverses opioid-induced constipation and analgesiaJ Pain Symptom Manage2002231485311779668
   PubMed Web of Science ®Google Scholar
• MeissnerWLeyendeckerPMueller-LissnerSNadstawekJHoppMRuckesCA randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipationEur J Pain2009131566418762438
   PubMed Web of Science ®Google Scholar
• LowensteinOLeyendeckerPHoppMSchutterURogersPDUhlRCombined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trialExpert Opin Pharmacother200910453154319243306
   PubMed Web of Science ®Google Scholar
• SimpsonKLeyendeckerPHoppMMuller-LissnerSLowensteinODeAJFixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer painCurr Med Res Opin200824123503351219032132
   PubMed Web of Science ®Google Scholar
• BrownDRGoldbergLIThe use of quaternary narcotic antagonists in opiate researchNeuropharmacology19852431811912986035
   PubMed Web of Science ®Google Scholar
• HolzerPOpioids and opioid receptors in the enteric nervous system: from a problem in opioid analgesia to a possible new prokinetic therapy in humansNeurosci Lett2004636113192195
   Google Scholar
• YuanCSFossJFO’ConnorMToledanoARoizenMFMossJMethylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trialClin Pharmacol Ther19965944694758612393
   PubMed Web of Science ®Google Scholar
• YuanCSFossJFO’ConnorMOsinskiJKarrisonTMossJMethylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trialJAMA200019; 2833367372
   Web of Science ®Google Scholar
• ThomasJKarverSCooneyGAChamberlainBHWattCKSlatkinNEMethylnaltrexone for opioid-induced constipation in advanced illnessN Engl J Med2008358222332234318509120
   PubMed Web of Science ®Google Scholar
• SlatkinNThomasJLipmanAGWilsonGBoatwrightMLWellmanCMethylnaltrexone for treatment of opioid-induced constipation in advanced illness patientsJ Support Oncol200971394619278178
   PubMedGoogle Scholar
• Wyeth PharmaceuticalsMethylnaltrexone Summary of product CharacteristicsElectronic Medicines Compendium2008 [cited 2009 Jun 5]; Available from: URL: http://emc.medicines.org.uk/medicine/20982/SPC/Relistor/
   Google Scholar
• YuanCSFossJFOsinskiJToledanoARoizenMFMossJThe safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit timeClin Pharmacol Ther19976144674759129564
   PubMed Web of Science ®Google Scholar
• YuanCSFossJFO’ConnorMKarrisonTOsinskiJRoizenMFEffects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit timeClin Pharmacol Ther200067439840410801249
   PubMed Web of Science ®Google Scholar
• ZimmermanDMGiddaJSCantrellBESchoeppDDJohnsonBGLeanderJDDiscovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid ++ antagonist for the treatment of gastrointestinal motility disordersJ Med Chem199422;371522622265
   Web of Science ®Google Scholar
• FossJFFisherDMSchmithVDPharmacokinetics of alvimopan and its metabolite in healthy volunteers and patients in postoperative ileus trialsClin Pharmacol Ther200883577077617653140
   PubMed Web of Science ®Google Scholar
• CamilleriMAlvimopan, a selective peripherally acting mu-opioid antagonistNeurogastroenterol Motil200517215716515787936
   PubMed Web of Science ®Google Scholar
• LiuSSHodgsonPSCarpenterRLFrickeJRJrADL 8–2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesiaClin Pharmacol Ther2001691667111180040
   PubMed Web of Science ®Google Scholar
• TaguchiASharmaNSaleemRMSesslerDICarpenterRLSeyedsadrMSelective postoperative inhibition of gastrointestinal opioid receptorsN Engl J Med20013451393594011575284
   PubMed Web of Science ®Google Scholar
• HerzogTJColemanRLGuerrieriJPJrGabrielKDuWTechnerLA double-blind, randomized, placebo-controlled phase III study of the safety of alvimopan in patients who undergo simple total abdominal hysterectomyAm J Obstet Gynecol2006195244545316626607
   PubMed Web of Science ®Google Scholar
• DelaneyCPWeeseJLHymanNHBauerJTechnerLGabrielKPhase III trial of alvimopan, a novel, peripherally acting, mu opioid antagonist, for postoperative ileus after major abdominal surgeryDis Colon Rectum20054861114112515906123
   PubMed Web of Science ®Google Scholar
• WebsterLJansenJPPeppinJLaskoBIrvingGMorlionBAlvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer painPain2008137242844018164818
   PubMed Web of Science ®Google Scholar
• PaulsonDMKennedyDTDonovickRACarpenterRLCherubiniMTechnerLAlvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction – a 21-day treatment-randomized clinical trialJ Pain20056318419215772912
   PubMed Web of Science ®Google Scholar
• MossJRosowCEDevelopment of peripheral opioid antagonists’ new insights into opioid effectsMayo Clin Proc200883101116113018828971
   PubMed Web of Science ®Google Scholar
• ThomasJOpioid-induced bowel dysfunctionJ Pain Symptom Manage200835110311317981003
   PubMed Web of Science ®Google Scholar
• McNicolEDBoyceDSchumannRCarrDBMu-opioid antagonists for opioid-induced bowel dysfunctionCochrane Database Syst Rev20082CD00633218425947
   PubMed Web of Science ®Google Scholar
• Greenwood-VanMBGardnerCJLittlePJHicksGAHaven-HudkinsDLPreclinical studies of opioids and opioid antagonists on gastrointestinal functionNeurogastroenterol Motil200416 Suppl 2465315357851
   PubMed Web of Science ®Google Scholar
• KaufmanPNKrevskyBMalmudLSMaurerAHSomersMBSiegelJARole of opiate receptors in the regulation of colonic transitGastroenterology1988946135113562834257
   PubMed Web of Science ®Google Scholar
• ManiARMooreKPNew insights into the role of endogenous opioids in the pathogenesis of gastrointestinal and liver diseaseGut200958789389519520882
   PubMed Web of Science ®Google Scholar
• YuanCSFossJFMossJEffects of methylnaltrexone on morphine-induced inhibition of contraction in isolated guinea-pig ileum and human intestineEur J Pharmacol19952761–21071117781680
   PubMed Web of Science ®Google Scholar
• YuanCSDoshanHCharneyMRO’ConnorMKarrisonTMaleckarSATolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humansJ Clin Pharmacol200545553854615831777
   PubMed Web of Science ®Google Scholar
• KreekMJSchaeferRAHahnEFFishmanJNaloxone, a specific opioid antagonist, reverses chronic idiopathic constipationLancet1983183192612626130292
   PubMed Web of Science ®Google Scholar
• BeattieDTCheruvuMMaiNO’KeefeMJohnson-RabidouxSPetersonCThe in vitro pharmacology of the peripherally restricted opioid receptor antagonists, alvimopan, ADL 08-0011 and methylnaltrexoneNaunyn Schmiedebergs Arch Pharmacol2007375320522017340127
   PubMed Web of Science ®Google Scholar
• BohnLMRaehalKMOpioid receptor signaling: relevance for gastrointestinal therapyCurr Opin Pharmacol20066655956316935560
   PubMed Web of Science ®Google Scholar
• SykesNYuanCSUsing oral naloxone in management of opioid bowel dysfunctionHandbook of Opioid Bowel DysfunctionNew YorkHaworth Medical Press2005175195
   Google Scholar
• BreivikHChernyNCollettBDeCFFilbetMFoubertAJCancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudesAnn Oncol20092081420143319244085
   PubMed Web of Science ®Google Scholar
• TraceyINeuroimaging of pain mechanismsCurr Opin Support Palliat Care20071210911618685351
   PubMedGoogle Scholar
• WiseRGRogersRPainterDBantickSPloghausAWilliamsPCombining fMRI with a pharmacokinetic model to determine which brain areas activated by painful stimulation are specifically modulated by remifentanilNeuroimage2002164999101412202088
   PubMed Web of Science ®Google Scholar
• PerssonKHammarlund-UdenaesMMortimerORaneAThe postoperative pharmacokinetics of codeineEur J Clin Pharmacol19924266636661623909
   PubMed Web of Science ®Google Scholar
• LeppertWLuczakJThe role of tramadol in cancer pain treatment – a reviewSupport Care Cancer200513151715668743
   PubMed Web of Science ®Google Scholar
• BuetlerTMWilder-SmithOHWilder-SmithCHAebiSCernyTBrenneisenRAnalgesic action of i.v. morphine-6-glucuronide in healthy volunteersBr J Anaesth2000841979910740556
   PubMed Web of Science ®Google Scholar
• GourlayGKCherryDACousinsMJA comparative study of the efficacy and pharmacokinetics of oral methadone and morphine in the treatment of severe pain in patients with cancerPain19862532973123528988
   PubMed Web of Science ®Google Scholar
• HoskinPJHanksGWAherneGWChapmanDLittletonPFilshieJThe bioavailability and pharmacokinetics of morphine after intravenous, oral and buccal administration in healthy volunteersBr J Clin Pharmacol19892744995052719903
   PubMed Web of Science ®Google Scholar
• McQuayHJCarrollDFauraCCGavaghanDJHandCWMooreRAOral morphine in cancer pain: influences on morphine and metabolite concentrationClin Pharmacol Ther19904832362442401122
   PubMed Web of Science ®Google Scholar
• SearJWHandCWMooreRAMcQuayHJStudies on morphine disposition: influence of renal failure on the kinetics of morphine and its metabolitesBr J Anaesth198962128322644963
   PubMed Web of Science ®Google Scholar
• LalovicBKharaschEHofferCRislerLLiu-ChenLYShenDDPharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolitesClin Pharmacol Ther200679546147916678548
   PubMed Web of Science ®Google Scholar
• HeiskanenTOlkkolaKTKalsoEEffects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodoneClin Pharmacol Ther19986466036119871425
   PubMed Web of Science ®Google Scholar
• KalsoEHow different is oxycodone from morphine?Pain20075;1323227228
   Web of Science ®Google Scholar
• NielsenCKRossFBLotfipourSSainiKSEdwardsSRSmithMTOxycodone and morphine have distinctly different pharmacological profiles: radioligand binding and behavioural studies in two rat models of neuropathic painPain2007132328930017467904
   PubMed Web of Science ®Google Scholar
• PoyhiaRSeppalaTOlkkolaKTKalsoEThe pharmacokinetics and metabolism of oxycodone after intramuscular and oral administration to healthy subjectsBr J Clin Pharmacol19923366176211389934
   PubMed Web of Science ®Google Scholar
• BrueraEBelzileMPituskinEFainsingerRDarkeAHarsanyiZRandomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer painJ Clin Oncol19981610322232299779695
   PubMed Web of Science ®Google Scholar
• LaurettiGROliveiraGMPereiraNLComparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patientsBr J Cancer200389112027203014647133
   PubMed Web of Science ®Google Scholar
• KirvelaMLindgrenLSeppalaTOlkkolaKTThe pharmacokinetics of oxycodone in uremic patients undergoing renal transplantationJ Clin Anesth1996813188695073
   PubMed Web of Science ®Google Scholar
• DonnerBZenzMTrybaMStrumpfMDirect conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer painPain19966435275348783318
   PubMed Web of Science ®Google Scholar
• MatherLEClinical pharmacokinetics of fentanyl and its newer derivativesClin Pharmacokinet1983854224466226471
   PubMed Web of Science ®Google Scholar
• EapCBBuclinTBaumannPInterindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependenceClin Pharmacokinet200241141153119312405865
   PubMed Web of Science ®Google Scholar
• InturrisiCEColburnWAKaikoRFHoudeRWFoleyKMPharmacokinetics and pharmacodynamics of methadone in patients with chronic painClin Pharmacol Ther19874143924013829576
   PubMed Web of Science ®Google Scholar
• RipamontiCGroffLBrunelliCPolastriDStavrakisADe ConnoFSwitching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio?J Clin Oncol19981610321632219779694
   PubMed Web of Science ®Google Scholar
• BaseltRCCasarettLJBiliary and urinary elimination of methadone and its metabolites in the ratBiochem Pharmacol19722120270427124647078
   PubMed Web of Science ®Google Scholar
• ConeEJGorodetzkyCWYousefnejadDBuchwaldWFJohnsonREThe metabolism and excretion of buprenorphine in humansDrug Metab Dispos19841255775816149907
   PubMed Web of Science ®Google Scholar
• Electronic Medicines Compendium, Napp pharmaceuticals limitedTranstec (buprenorphine) transdermal patchSummary of product characteristicsElectronic Medicines Compendium2007 Available from: URL: http://emc.medicines.org.uk/document.aspx?documentId=8864
   Google Scholar
• SittlRLikarRNautrupBPEquipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort studyClin Ther200527222523715811486
   PubMed Web of Science ®Google Scholar
• SittlRTransdermal buprenorphine in cancer pain and palliative carePalliat Med200620 Suppl 1s25s3016764218
   PubMed Web of Science ®Google Scholar
• GalTJNaloxone reversal of buprenorphine-induced respiratory depressionClin Pharmacol Ther198945166712491980
   PubMed Web of Science ®Google Scholar
• ZhengMMcErlaneKMOngMCHydromorphone metabolites: isolation and identification from pooled urine samples of a cancer patientXenobiotica200232542743912065064
   PubMed Web of Science ®Google Scholar
• MurrayAHagenNAHydromorphoneJ Pain Symptom Manage2005295 SupplS57S6615907647
   PubMed Web of Science ®Google Scholar
• ParabPVRitschelWACoyleDEGreggRVDensonDDPharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjectsBiopharm Drug Dispos1988921871992453226
   PubMed Web of Science ®Google Scholar
• VallnerJJStewartJTKotzanJAKirstenEBHonigbergILPharmacokinetics and bioavailability of hydromorphone following intravenous and oral administration to human subjectsJ Clin Pharmacol19812141521566165742
   PubMed Web of Science ®Google Scholar
• SarhillNWalshDNelsonKAHydromorphone: pharmacology and clinical applications in cancer patientsSupport Care Cancer200192849611305075
   PubMed Web of Science ®Google Scholar
• BabulNDarkeACHagenNHydromorphone metabolite accumulation in renal failureJ Pain Symptom Manage19951031841867543126
   PubMed Web of Science ®Google Scholar
• KharaschEDRussellMMautzDThummelKEKunzeKLBowdleAThe role of cytochrome P450 3A4 in alfentanil clearance. Implications for interindividual variability in disposition and perioperative drug interactionsAnesthesiology199787136509232132
   PubMed Web of Science ®Google Scholar
• StanskiDRThe clinical pharmacology of alfentanilEur J Anaesthesiol Suppl198713113126052
   PubMedGoogle Scholar
• MeuldermansWvan PeerAHendrickJAlfentanil pharmacokinetics and metabolism in humansAnesthesiology1998695275343140690
   PubMed Web of Science ®Google Scholar
• KentAPDodsonMEBowerSThe pharmacokinetics and clinical effects of a low dose of alfentanil in elderly patientsActa Anaesthesiol Belg198839125332897149
   PubMedGoogle Scholar
• MercadanteSCasuccioAFulfaroFGroffLBoffiRVillariPSwitching from morphine to methadone to improve analgesia and tolerability in cancer patients: a prospective studyJ Clin Oncol200119112898290411387363
   PubMed Web of Science ®Google Scholar
• RossJRRutterDWelshKJoelSPGollerKWellsAUClinical response to morphine in cancer patients and genetic variation in candidate genesPharmacogenomics J20055532433616103897
   PubMed Web of Science ®Google Scholar
• RossJRRileyJTaegetmeyerABSatoHGrettonSdu BoisRMGenetic variation and response to morphine in cancer patients: catechol-o-methyltransferase and multidrug resistance-1 gene polymorphisms are associated with central side effectsCancer200811261390140318257092
   PubMed Web of Science ®Google Scholar
• RakvagTTKlepstadPBaarCKvamTMDaleOKaasaSThe Val158Met polymorphism of the human catechol-O-methyltransferase (COMT) gene may influence morphine requirements in cancer pain patientsPain20051161–2737815927391
   PubMed Web of Science ®Google Scholar
• RakvagTTRossJRSatoHSkorpenFKaasaSKlepstadPGenetic variation in the catechol-O-methyltransferase (COMT) gene and morphine requirements in cancer patients with painMol Pain200846419094200
   PubMed Web of Science ®Google Scholar
• LefkowitzRJShenoySKTransduction of receptor signals by beta-arrestinsScience2005308572151251715845844
   PubMed Web of Science ®Google Scholar
• ShenoySKMcDonaldPHKohoutTALefkowitzRJRegulation of receptor fate by ubiquitination of activated beta 2-adrenergic receptor and beta-arrestinScience200129455451307131311588219
   PubMed Web of Science ®Google Scholar
• HoltheMRakvagTNKlepstadPIdleJRKaasaSKrokanHESequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patientsPharmacogenomics J200331172612629580
   PubMed Web of Science ®Google Scholar
• HoltheMKlepstadPZahlsenKBorchgrevinkPCHagenLDaleOMorphine glucuronide-to-morphine plasma ratios are unaffected by the UGT2B7 H268Y and UGT1A1*28 polymorphisms in cancer patients on chronic morphine therapyEur J Clin Pharmacol200258535335612185559
   PubMed Web of Science ®Google Scholar